Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

GenMark announces dismissal of microfluidic technology patent lawsuit against Caliper Life Sciences

GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.

2 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

San Diego Hospice is California's first provider of unique children care program

The Comprehensive Care Management Programs at San Diego Hospice celebrates one year as California's first provider of Partners for Children. This unique state-funded program allows chronically ill children on Medi-Cal and CCS to receive pain and symptom management services, or palliative care, at home.

1 Mar 2011

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

28 Feb 2011

Acute viral infection does not appear to cause exacerbation of IPF

Acute viral infection does not appear to be a primary cause of acute exacerbation of idiopathic pulmonary fibrosis, a progressive, deadly disease resulting in thickening and scarring of the lungs, according to a study conducted by researchers from the U.S., Korea and Japan.

28 Feb 2011

FDA approves GSK's PROMACTA to treat rare blood disorder

GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

27 Feb 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

New DNA technology to study cystic fibrosis 'superbug' during infection

The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. Scientists at Liverpool identified a particularly virulent strain of the bacteria that is transmissible between patients. The Liverpool Epidemic Strain (LES), referred to as a cystic fibrosis 'superbug', can cause aggressive infection and results in progressive lung decline.

23 Feb 2011

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Life Technologies Corporation, today announced Dr. Angel Carracedo and Dr. Mark Pallen as the winners of the European Ion Torrent Personal Genome Machine (PGM™) Sequencer Grants Program.

19 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Inspire announces strategic corporate restructuring on its eye care business

Inspire Pharmaceuticals, announced today a strategic corporate restructuring designed to result in the Company focusing activities on its eye care business, allowing it to fully leverage existing commercial capabilities, pipeline assets and related corporate development and licensing opportunities.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Single donor gifts lungs for two lung transplants

The University of Michigan Transplant Center celebrated a milestone recently, performing its 500th lung transplant. But there's much more to this story than a number.

17 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

RPCs transplant appears to improve kidney structure and function in rat models

Transplanting autologous renal progenitor cells, into rat models with kidney damage from pyelonephritis - a type of urinary infection that has reached the kidney - has been found to improve kidney structure and function.

14 Feb 2011

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it received the interim report of its phase 2-3 trial to treat Alpha-1 deficiency with its flag product, Alpha-Antitrypsin, delivered by inhalation.

14 Feb 2011

Registration open for idiopathic pulmonary fibrosis healthcare summit

The Pulmonary Fibrosis Foundation (PFF) announced today that registration is now open for the IPF Summit 2011: From Bench to Bedside. The conference will feature an innovative two-day continuing medical education (CME) program for physicians, researchers, and other health care professionals. Additionally there will be a separate one-day patient, family member, and caregiver program to address the growing educational needs of the idiopathic pulmonary fibrosis (IPF) community.

14 Feb 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Resistance to leptin, a protein that plays a key role in regulating metabolism and appetite, may help prevent the development of acute respiratory distress syndrome and acute lung injury in individuals with type II diabetes, according to a study conducted by researchers in Chicago.

13 Feb 2011

Fibrosis News and Research

Further Reading

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

GenMark announces dismissal of microfluidic technology patent lawsuit against Caliper Life Sciences

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

San Diego Hospice is California's first provider of unique children care program

Scripps Health offers genetic testing to patients with Hepatitis C

Acute viral infection does not appear to cause exacerbation of IPF

FDA approves GSK's PROMACTA to treat rare blood disorder

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

New DNA technology to study cystic fibrosis 'superbug' during infection

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Inspire announces strategic corporate restructuring on its eye care business

Inspire fourth quarter revenues increase 2% to $30.3 million

Single donor gifts lungs for two lung transplants

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

RPCs transplant appears to improve kidney structure and function in rat models

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Registration open for idiopathic pulmonary fibrosis healthcare summit

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News